Skip to main content
Caplight Logo









CellFE

CellFE

Private
Alameda, CaliforniaHealthcare & Life Scienceshttps://www.cellfebiotech.com/

Last Round

Series A

Sep 27, 2023

Total Funding Raised

$26.8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

CellFE is a biotechnology company that develops a microfluidic-based intracellular gene delivery platform for transporting gene-editing molecules into human cells to enhance cell therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS

AI Layer

Non-AI

Keywords

cell therapy manufacturingmicrofluidicsnon-viral gene deliverymechanoporationCAR-T therapycellular engineeringbioprocessinggene editinglife science toolscell engineering platformtransfectionbenchtop instrumentationbiotech hardwarerazor-and-blade modelcell therapy scale-up

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CellFE Comparables

Compare CellFE with similar companies based on industry and business-model similarity.

CellFE comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Indee Labs
87%
Portal Biotechnologies
86%
Avectas
85%

CellFE Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 27, 2023
SeedMar 31, 2020
GrantAug 27, 2019

Key People

Founding team and executive leadership

Todd Sulchek

Chief Scientific Officer, Co-Founder

Founding Team

Alla Zamarayeva

Co-founder And CEO

Founding Team

CellFE Investors

Notable investors and investment history

CellFE investors
InvestorRounds
GreatPoint VenturesSeries A
Cota CapitalSeries A, Seed
Dynamk CapitalSeries A, Seed
Khosla VenturesSeries A
Embark VenturesSeed, Series A
M VenturesSeries A
Elm Street VenturesSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 115% MoM, reaching 1.9K.

  • Apr 30, 2025

    Collaborating with Tcelltech GmbH to advance cell therapy development.

CellFE Filings

Explore SEC and related filing metadata, where available.

CellFE filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about CellFE's valuation, stock price, and market status.

Is CellFE a public or private company?

CellFE is a private company.

What is the current stock price of CellFE?

CellFE is a private company with no public stock price. No recent secondary market data is available.

How much is CellFE worth (valuation)?

Valuation information for CellFE is not publicly available.

Can I buy CellFE stock?

CellFE shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was CellFE's last funding round?

CellFE's most recent funding round was Series A on September 27, 2023.

Who are the main investors in CellFE?

Key investors in CellFE include Cota Capital, Dynamk Capital, M Ventures.

Will CellFE IPO soon?

No public IPO plans have been announced for CellFE.

How can I track CellFE secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CellFE's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAlameda, California
Employee Range15
Year Founded2018
Last FundingSep 27, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?